Hemoglobin Oxygen Therapeutics ^{Filed, US Offering, Removed, Nasdaq: HOTI}

We are a biotechnology company focused on the development, manufacture, and commercialization of a proprietary technology platform for oxygen-carrying solutions that address critical unmet medical needs in both human and veterinary medicine. Using our patents, proprietary technology and know-how, we develop and sell products that, under certain conditions, are a possible alternative to blood transfusions to deliver oxygen to organs and tissues. Through numerous clinical studies, our products have been shown to address many of the current limitations that exist for blood transfusion. These include the limited shelf life of blood, logistical challenges of typing/cross-matching, delays in testing for pathogens, and blood shortages during times of high need and/or insufficient donations. We have significant experience gained through extensive pre-clinical and clinical testing of these products, which have a well-understood and extensively documented safety and efficacy profile.